Fludarabine (marketed as
fludarabine phosphate under the trade name
Fludara) is a
chemotherapy drug used in the treatment of
hematological malignancies.
Indications
Fludarabine is highly effective in the treatment of chronic lymphocytic leukemia, producing higher response rates than
alkylating agents such as
chlorambucil alone.
Fludarabine is used in various combinations with
cyclophosphamide,
mitoxantrone,
dexamethasone and
rituximab in the treatment of indolent
non-Hodgkins lymphomas. As part of the
FLAG regimen, fludarabine is used together with
cytarabine and
granulocyte colony-stimulating factor in the treatment of
acute myeloid leukaemia. Because of its immunosuppressive effects, fludarabine is also used in some conditioning regimens prior to
non myeloablative allogeneic stem cell transplant.
Pharmacology
Fludarabine is a
purine analog, and can be given both orally and intravenously. Fludarabine inhibits
DNA synthesis by interfering with
ribonucleotide reductase and
DNA polymerase. It is active against both dividing and resting cells.
Side effects
Fludarabine is associated with profound lymphopenia, and as a consequence, increases the risk of
opportunistic infections significantly. Patients who have been treated with fludarabine will usually be asked to take
co-trimoxazole or to use monthly nebulised
pentamidine to prevent
Pneumocystis jiroveci pneumonia. The profound lymphopenia caused by fludarabine renders patients susceptible to
transfusion-associated graft versus host disease, a fatal complication of
blood transfusion. For this reason, all patients who have ever received fludarabine should only be given
irradiated blood components.
Fludarabine causes anemia, thrombocytopenia and neutropenia, requiring regular blood count monitoring. Some patients require blood and platelet transfusion, or G-CSF injections to boost neutrophil counts.
Fludarabine is associated with the development of severe autoimmune hemolytic anemia in a proportion of patients.
Difficulties are often encountered when harvesting peripheral blood stem cells from patients previously treated with fludarabine.
References
External links